Details

Autor(en) / Beteiligte

• Ayzenberg, Ilya
• Schöllhammer, Joanna
• Hoepner, Robert
• Hellwig, Kerstin
• Ringelstein, Marius
• Aktas, Orhan
• Kümpfel, Tania
• Krumbholz, Markus
• Trebst, Corinna
• Paul, Friedemann
• Pache, Florence
• Obermann, Mark
• Zeltner, Lena
• Schwab, Matthias
• Berthele, Achim
• Jarius, Sven
• Kleiter, Ingo

Titel

Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study

Ist Teil von

• Journal of neurology, 2016-03, Vol.263 (3), p.575-582

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• Glatiramer acetate (GA) is an approved therapy for relapsing–remitting multiple sclerosis, but its efficacy for the prevention of attacks in neuromyelitis optica spectrum disorder (NMOSD) remains unknown. We did a multicenter retrospective analysis of GA-treated patients with NMOSD, identified through a national registry. Annualized relapse rate and expanded disability status scale (EDSS) were the main outcome measures. We identified 23 GA-treated patients (21 female, 16 aquaporin-4 antibody-positive). GA was given for <6 months in seven patients; reasons for stopping were relapses ( n  = 3), confirmation of NMOSD ( n  = 2) and side effects ( n  = 2). Of 16 patients treated ≥6 months with GA (15 female, 11 aquaporin-4 antibody-positive), 14 experienced at least one relapse. There was no reduction in the mean annualized relapse rate in the total group (1.9 ± 1.1 before vs. 1.8 ± 1.4 during GA therapy), as well as in those patients who were aquaporin-4 antibody-positive, or had a history of prior immunotherapy or not. The median EDSS increased (2.5 start vs. 3.5 finish of GA, P  < 0.05). GA therapy was discontinued in 15/16 patients; reasons were therapeutic inefficacy in 13 and post-injection skin reactions in two patients. We conclude that GA is not beneficial for preventing attacks in most patients with NMOSD, particularly in aquaporin-4 antibody-positive cases.